Araris Biotech is a biotechnology company that develops antibody-drug conjugates using a proprietary linker technology designed for efficient payload attachment without antibody engineering. The company's platform enables the creation of stable, homogenous ADCs with improved therapeutic efficacy and reduced side effects. The company focuses on advancing targeted cancer treatments by streamlining the ADC development process.